公开(公告)号：WO2021252054A1

公开(公告)日：2021-12-16

申请号：PCT/US2021/025754

申请日：2021-04-05

申请人： OCULAR SCIENCE, INC.

发明人： SAMPIETRO, Anthony ,  GOLDBERG, Damien ,  FROST, Amy ,  HOLDORF, Brian ,  MAH, Francis

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K9/08 ,  A61K31/4709 ,  A61K31/573 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61K47/02 ,  A61K9/0048

摘要： Provided herein are certain preservative-free ophthalmic formulations for post-operative ocular care.

公开(公告)号：WO2020237248A8

公开(公告)日：2020-11-26

申请号：PCT/US2020/042414

申请日：2020-07-16

申请人： OCULAR SCIENCE, INC.

发明人： SAMPIETRO, Anthony ,  GOLDBERG, Damien ,  FROST, Amy ,  HOLDORF, Brian

IPC分类号： A61B3/00 ,  A61F2/16 ,  A61F9/007 ,  A61K31/135 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/44 ,  A61K47/02 ,  A61K47/10 ,  A61K47/186 ,  A61K47/34 ,  A61K9/0048

摘要： Provided herein are certain preservative-free ophthalmic formulations for the treatment of presbyopia. In some embodiments, the formulation may include pilocarpine HCl, phenylephrine HCl, pheniramine maleate, and ketorolac tromethamine as the active pharmaceutical ingredients. In some embodiments, administration of the combined formulation to presbyopia patients may offer several advantages as compared to administration of the active pharmaceutical ingredients separately.

公开(公告)号：WO2023069962A1

公开(公告)日：2023-04-27

申请号：PCT/US2022/078321

申请日：2022-10-18

申请人： OCULAR SCIENCE, INC.

发明人： FROST, Amy ,  HOLDORF, Brian ,  GARNER, Eric ,  SAMPIETRO, Anthony ,  LEUNG, Dennis

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K47/02 ,  A61K47/10 ,  A61K31/46 ,  A61P27/02 ,  A61P27/10

摘要： Provided herein are certain ophthalmic formulations for post-operative ocular care.

公开(公告)号：WO2020237248A1

公开(公告)日：2020-11-26

申请号：PCT/US2020/042414

申请日：2020-07-16

申请人： OCULAR SCIENCE, INC.

发明人： SAMPIETRO, Anthony ,  GOLDBERG, Damien ,  FROST, Amy ,  HOLDORF, Brian

IPC分类号： A61B3/00 ,  A61F2/16 ,  A61F9/007

摘要： Provided herein are certain preservative-free ophthalmic formulations for the treatment of presbyopia. In some embodiments, the formulation may include pilocarpine HCl, phenylephrine HCl, pheniramine maleate, and ketorolac tromethamine as the active pharmaceutical ingredients. In some embodiments, administration of the combined formulation to presbyopia patients may offer several advantages as compared to administration of the active pharmaceutical ingredients separately.